BioIQ and Biomeme Announce Partnership for COVID Testing, Bringing the RT-PCR Laboratory and Gold-Standard Testing to the Worksite for Fast and Highly Sensitive Results

BioIQ, an analytics-driven population health engagement and testing platform company for top employers and health plans, announces a partnership with Biomeme, a leading manufacturer of portable, real-time PCR testing solutions. The collaboration brings Biomeme’s highly accurate, mobile RT-PCR COVID-19 test to BioIQ’s COVID testing platform and on-site testing events, eliminating latency associated with sending samples away and false negatives/false positives associated with less sensitive, lower accuracy point-of-care molecular and antigen tests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005757/en/

The field-ready testing solution has gold-standard sensitivity and specificity associated with lab-based RT-PCR tests and produces test results on several dozens of samples within two hours and over 1,500 samples in a standard eight-hour period. In tandem with the BioIQ digital diagnostic testing platform, the solutions bring speed, scientific rigor, and structure to worksite, retail, and public health COVID testing events.

BioIQ’s platform offers employers, health plans, and participants centralized access to registration, scheduling, and test results, with integrated telehealth consultation and follow-up. Reporting, contact tracing, and case tracking simplify program management and streamline employee and member throughput. In partnership with Biomeme, consumers benefit from fast, accurate, and convenient testing anywhere, coupled with a consumer-friendly digital experience at each step of the patient journey.

“The U.S. has made strides around COVID-19 test and vaccine access but continues to struggle with administering these vital resources in workflows that benefit consumers and enterprises,” said Sean Slovenski, BioIQ CEO.

“Through our partnership with Biomeme, we’re able to bring a unique, portable, fast, and highly sensitive RT-PCR test—the gold standard for accurately detecting COVID-19—on-site. This enables us to offer employers, health plans, and consumers reliable, real-time test results within a framework that brings structure and organization to infectious disease testing and vaccination programs,” said Justin Bellante, BioIQ Founder, President, and COO.

“Biomeme’s innovative mobile RT-PCR COVID-19 test brings higher throughput, lab standard performance to on-site testing events,” said Max Perelman, Biomeme co-founder. “Our battery-powered device and shelf-stable test, which detects all of the new major SARS-CoV-2 variants, is the perfect complement to BioIQ’s digital platform. Together, we bring businesses and health plans unparalleled testing sensitivity and accuracy, higher employee and member testing throughput, and fast and highly sensitive results on-site, culminating in an improved participant experience.”

Biomeme disrupted molecular diagnostics nine years ago when they created the first smart phone add-on capable of performing real-time PCR in the field. Prior to the COVID-19 pandemic, Biomeme provided their full suite of end-to-end mobile molecular solutions to a variety of industries, including biodefense, aquatic ecology, industrial QC, food and water safety, vector surveillance, and even veterinary to enable real-time pathogen detection and disease surveillance at the point of need. As a necessary step to control the unexpected, novel, and devastating COVID-19 disease, Biomeme launched their portable platform comprising simple DNA/RNA extraction and purification, shelf-stable lyophilized real-time PCR assays, hand-held qPCR thermocyclers, mobile apps, a cloud portal, and a robust web API, into the human diagnostics market.

The rapidly growing Biomeme team continues to design and manufacture their SARS-CoV-2 tests to alleviate the challenges to global supply chains during the pandemic. To learn more about Biomeme’s various testing solutions, empowering anyone anywhere with the capabilities of a central lab in the palm of their hand, visit www.biomeme.com.

BioIQ’s COVID and infectious disease platform encompasses on-site, retail, and home self-collection workflows across a variety of test types, including nasal and saliva RT-PCR molecular tests, antigen tests, and antibody tests, all within a consumer-friendly digital experience. In addition, BioIQ works with multiple Fortune 100 companies and more than 40 national health plans representing seven out of 10 fully insured Americans on over 30 testing and immunization program solutions. BioIQ helps these employers and health plans access a flexible national network of testing options, implement convenient, analytics-driven testing programs, and manage the patient journey from end to end.

To learn more about BioIQ’s COVID-19 testing programs and solutions, as well as other services to protect workforces and communities from disease, visit www.bioiq.com.

About BioIQ

BioIQ is modernizing the diagnostic testing industry through a national network of labs and customized solutions that support payors, employers, and consumers. By aggregating testing solutions, optimizing lab capacity, and integrating testing with customers’ needs and strategies, BioIQ ensures resilience and reliability so that employers and payors can protect workforces and members. With its first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com.

About Biomeme

Biomeme was conceived and created to make the world a better place through the democratization of healthcare diagnostics. To that end, we have created technology that empowers anyone, anywhere (including low-resource settings with minimal space, electricity, and equipment) with the capabilities of a molecular lab in the palm of their hands. Over the last nine years, Biomeme has grown a vertically integrated organization spanning specimen collection, sample prep, assay, and instrumentation R&D, PCR reagent lyophilization, hardware, and consumable manufacturing, as well as molecular diagnostic testing services. With the low cost, ease-of-use, and unparalleled field portability of the Biomeme platform, we are uniquely poised to rapidly advance initiatives in emerging infectious diseases like COVID-19, as well as emergency preparedness, response, and recovery. For more information, visit biomeme.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005757/en/